# SUNPHARMA (SUNPHARMA) — Stock analysis

> Faxioms all-in-one stock review. Canonical page: https://faxioms.com/stocks/sunpharma

## Current market snapshot

- Exchange: BSE
- Country: India
- Price: ₹1,770.7
- Change: +0.61%
- As of: 2026-10-13
- 1D return: +0.61%
- 5D return: -1.85%
- 1M return: -3.77%
- Latest complete quarter: fy27_q1

## Faxioms Analysis

_As of 2026-10-12_

### Technical Outlook

As of October 12, 2026, Sun Pharma's technical setup presents a mixed picture across timeframes. Daily and weekly charts indicate a bearish trend, with the price trading below key moving averages and the Supertrend indicator. The daily trend shows established conviction with an ADX of 30.17, while the weekly trend is weaker with an ADX of 19.2. In contrast, the monthly chart displays a bullish Supertrend direction, though momentum is weak with an ADX of 9.28 and the price is below the 20-period EMA. The stock is positioned near the lower end of its recent trading ranges, with the 50-day and 20-day range positions at +5.0% and +10.2% respectively. Recent market activity shows one neutral event in the last 30 days, with no positive or negative attention events.

Participation and risk metrics reveal an annualized volatility of +20.5% and an ATR of 1.85%. The current drawdown stands at -12.0%, with a maximum drawdown of -17.3%. Key resistance is observed at ₹1762.6 (0.15% above current price), followed by ₹1765.64 (0.32% above). Nearest support is at ₹1748.4 (0.66% below current price), followed by ₹1736.8 (1.32% below). The current setup would be confirmed by a sustained break above the ₹1762.6 resistance level, while a close below ₹1748.4 support could signal further downside.

- Daily and weekly charts show a bearish trend, while the monthly chart indicates a bullish Supertrend direction.
- Daily trend conviction is established (ADX 30.17), but monthly momentum is weak (ADX 9.28).
- The stock is positioned near the lower end of its 50-day and 20-day trading ranges.
- Nearest resistance is at ₹1762.6 (0.15% above current price) and nearest support is at ₹1748.4 (0.66% below current price).
- A break above ₹1762.6 would confirm the setup, while a break below ₹1748.4 could signal further weakness.

- Inside Bar
- Harami
- Bullish Engulfing Reversal
- Outside Bar
- Shooting Star
- Evening Star

### News Context

Sun Pharmaceutical Industries' board is scheduled to consider a Non-Convertible Debenture (NCD) issuance of up to ₹15,000 crore on October 12, 2026. These debentures are intended to be issued through private placement, potentially in multiple tranches. This move indicates the company's strategy to raise significant capital, likely for funding its operations, expansion, or debt management. Separately, a report from October 11, 2026, highlighted that Indian pharmaceutical leaders, including Sun Pharma, are advocating for expedited clinical trials and a state-backed market for new drugs. This broader industry sentiment suggests a push towards innovation and improved market access within the Indian pharmaceutical sector.

- Sun Pharma's board to consider up to ₹15,000 crore NCD issue on October 12, 2026.
- NCDs proposed to be issued via private placement in one or more tranches.
- Industry leaders, including Sun Pharma, seek faster drug trials and state support for new medicines (Reported October 11, 2026).

- [Indian pharma leaders seek faster trials, state-backed market for new drugs](https://www.businesstoday.in/industry/pharma/story/indian-pharma-leaders-seek-faster-trials-state-backed-market-for-new-drugs-560883-2026-10-11)
- [Sun Pharmaceutical board to consider ₹15,000 crore NCD issue on October 12](https://www.cnbctv18.com/market/stocks/sun-pharmaceutical-share-price-board-to-consider-rs-15000-crore-ncd-issue-on-october-12-20007048.htm)

### What Changed

Sun Pharma, listed on the BSE, remains a prominent player in the Indian pharmaceutical sector. Recent industry discussions, as reported on October 11, 2026, indicate that leaders within the Indian pharmaceutical industry are advocating for accelerated clinical trial processes and the establishment of state-backed markets for novel drugs. This aligns with broader industry trends focused on innovation and global expansion, areas Sun Pharma has historically engaged in, such as its acquisition of Organon. The company's operational context within the Indian market and its strategic positioning in research and development appear to be ongoing themes.

- On October 11, 2026, news reported that Indian pharmaceutical leaders, including those from companies like Sun Pharma, are seeking faster clinical trials and state support for new drug markets.
- The discussion on October 11, 2026, highlights ongoing industry efforts towards innovation and global expansion within the Indian pharmaceutical sector.

- [Indian pharma leaders seek faster trials, state-backed market for new drugs](https://www.businesstoday.in/industry/pharma/story/indian-pharma-leaders-seek-faster-trials-state-backed-market-for-new-drugs-560883-2026-10-11)

### Official Filings

Sun Pharmaceutical Industries Limited has announced a board meeting scheduled for October 12, 2026, to consider fundraising activities. This follows recent disclosures regarding the company's strategic initiatives and operational updates. On October 1, 2026, the company released details about its LEQSELVI® (deuruxolitinib) drug, presenting two-year data showing sustained efficacy and safety in severe alopecia areata at the EADV Congress 2026. Additionally, a notice for a postal ballot was issued on October 1, 2026, seeking shareholder approval for several special resolutions. These include the adoption of the Sun Pharma Employees Stock Option Plan 2026 (ESOP 2026), which involves granting up to 12,000,000 options without dilution, and approvals for a proposed acquisition of Organon & Co. This acquisition may involve enhanced borrowing limits up to ₹700 billion and investment limits up to ₹800 billion, with potential encumbrance over Organon shares for financing facilities up to USD 12 billion. The company also published a notice on October 2, 2026, regarding the postal ballot and e-voting period, which runs from October 2 to October 31, 2026, with results expected by November 3, 2026. In other news, on October 6, 2026, Sun Pharma established the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai with a $2.5 million endowment. Furthermore, the company's ESG Overview for the fiscal year 2025-26, filed on September 29, 2026, highlighted a leadership transition and reported a 15.86% reduction in absolute Scope 1 and 2 carbon emissions, alongside sourcing 43% of energy from renewable sources against a 2020 baseline.

- Board meeting scheduled for October 12, 2026, to consider fundraising.
- Shareholder approval sought via postal ballot (October 2 - October 31, 2026) for ESOP 2026 and proposed acquisition of Organon & Co.
- Proposed acquisition of Organon & Co. may involve borrowing limits up to ₹700 billion and investment limits up to ₹800 billion.
- Endowed a Sun Professorship in Dermatology at Mount Sinai with a $2.5 million donation on October 6, 2026.
- ESG Overview for FY 2025-26 reported a 15.86% reduction in Scope 1 and 2 carbon emissions and 43% renewable energy sourcing.

- [Other business matters |Meeting Date: 12-Oct-2026](https://nsearchives.nseindia.com/corporate/SUNSEC_07102026203800_SEintimationofBMforNCD.pdf)
- [Board Meeting Intimation |Meeting Date: 12-Oct-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_370_WebXMLFile_20261007_204746791.xml)
- [Sun Pharamceutical Industries Limited has informed the Exchange about Board Meeting to be held on 12-Oct-2026 to consider Fund raising. |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_370_WebXMLFile_20261007_204746791.xml)
- [Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/SUNSEC_06102026182517_SEintimationPRforMSP.pdf)
- [Newspaper Publication about Postal Ballot/E-voting October 2026 |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SUNSEC_02102026171502_SE_intimation_for_PB_Newspaper_Advertisement.pdf)
- [Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 01, 2026, titled "New LEQSELVI® (deuruxolitinib) Two-YearData in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/SUNPHARMA123_01102026174411_SEIntimationPR_1Oct2026.pdf)
- [Notice of Postal Ballot October 2026 |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/SUNSEC_01102026184724_SEintimationfornoticeofpostalballot.pdf)
- [Sun Pharmaceutical Industries Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot |SUBJECT: Notice Of Shareholders Meetings-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_370_WebXMLFile_20261001_185747006.xml)
- [Newspaper Publication about the opening of Special Window for transfer of physical shares |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SUNSEC_30092026174654_SEIntimationfor_Special_Window_30092026.pdf)
- [Sun Pharmaceutical Industries Limited has informed the Exchange regarding 'ESG Overview for FY 2025-26'. |SUBJECT: Updates](https://nsearchives.nseindia.com/corporate/SUNSEC_29092026192130_ESGOVerview2025-26.pdf)

### Fundamentals

Sun Pharma reported sequential growth in its latest financial results. Revenue from operations increased to ₹15,299.88 crore in Q1 FY2026-27 from ₹14,611.79 crore in Q4 FY2025-26. Profit Before Tax also saw a sequential rise, reaching ₹4,098.81 crore in Q1 FY2026-27 compared to ₹3,551.34 crore in the prior quarter. However, the company recorded exceptional items before tax of -₹204.09 crore in Q1 FY2026-27, a decrease from ₹0.0 in Q4 FY2025-26, which may impact net profit conversion. Finance costs also increased sequentially from ₹85.89 crore to ₹99.67 crore.

- Revenue from operations increased sequentially to ₹15,299.88 crore in Q1 FY2026-27.
- Profit Before Tax rose sequentially to ₹4,098.81 crore in Q1 FY2026-27.
- Exceptional items before tax turned negative (-₹204.09 crore) in Q1 FY2026-27.
- The impact of exceptional items on net profit will be a key checkpoint for the next reporting period.

### Bull Case

Sun Pharma's monthly technical trend indicates a bullish setup, with the Supertrend direction showing positive momentum over this longer timeframe. The company's board is scheduled to consider a Non-Convertible Debenture (NCD) issue of up to ₹15,000 crore on October 12, 2026, which may be utilized for strategic initiatives or financial management.

- Monthly Supertrend direction is bullish as of 2026-10-12.
- Board to consider NCD issue of up to ₹15,000 crore on October 12, 2026.

- [Indian pharma leaders seek faster trials, state-backed market for new drugs](https://www.businesstoday.in/industry/pharma/story/indian-pharma-leaders-seek-faster-trials-state-backed-market-for-new-drugs-560883-2026-10-11)
- [Sun Pharmaceutical board to consider ₹15,000 crore NCD issue on October 12](https://www.cnbctv18.com/market/stocks/sun-pharmaceutical-share-price-board-to-consider-rs-15000-crore-ncd-issue-on-october-12-20007048.htm)
- [Other business matters |Meeting Date: 12-Oct-2026](https://nsearchives.nseindia.com/corporate/SUNSEC_07102026203800_SEintimationofBMforNCD.pdf)
- [Board Meeting Intimation |Meeting Date: 12-Oct-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_370_WebXMLFile_20261007_204746791.xml)
- [Sun Pharamceutical Industries Limited has informed the Exchange about Board Meeting to be held on 12-Oct-2026 to consider Fund raising. |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_370_WebXMLFile_20261007_204746791.xml)
- [Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/SUNSEC_06102026182517_SEintimationPRforMSP.pdf)
- [Newspaper Publication about Postal Ballot/E-voting October 2026 |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SUNSEC_02102026171502_SE_intimation_for_PB_Newspaper_Advertisement.pdf)
- [Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 01, 2026, titled "New LEQSELVI® (deuruxolitinib) Two-YearData in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/SUNPHARMA123_01102026174411_SEIntimationPR_1Oct2026.pdf)
- [Notice of Postal Ballot October 2026 |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/SUNSEC_01102026184724_SEintimationfornoticeofpostalballot.pdf)
- [Sun Pharmaceutical Industries Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot |SUBJECT: Notice Of Shareholders Meetings-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_370_WebXMLFile_20261001_185747006.xml)

### Bear Case

Sun Pharma's daily technical indicators suggest a weakening trend, with the Super Trend direction noted as bearish as of October 12, 2026. This is accompanied by negative slopes in the 20-day and 50-day Simple Moving Averages (SMA). While monthly trends indicate a bullish Super Trend, the recent daily and weekly technicals show a bearish direction. The company's board is scheduled to consider a Non-Convertible Debenture (NCD) issue of up to ₹15,000 crore, which could impact its capital structure.

- Daily technicals show a bearish Super Trend direction as of October 12, 2026.
- The 20-day and 50-day SMAs exhibit negative slopes on a daily basis.
- The company's board will consider a potential NCD issuance of up to ₹15,000 crore.
- Recent returns show a -4.3% change over the last month and a -9.1% change over the last three months.

- [Indian pharma leaders seek faster trials, state-backed market for new drugs](https://www.businesstoday.in/industry/pharma/story/indian-pharma-leaders-seek-faster-trials-state-backed-market-for-new-drugs-560883-2026-10-11)
- [Sun Pharmaceutical board to consider ₹15,000 crore NCD issue on October 12](https://www.cnbctv18.com/market/stocks/sun-pharmaceutical-share-price-board-to-consider-rs-15000-crore-ncd-issue-on-october-12-20007048.htm)
- [Other business matters |Meeting Date: 12-Oct-2026](https://nsearchives.nseindia.com/corporate/SUNSEC_07102026203800_SEintimationofBMforNCD.pdf)
- [Board Meeting Intimation |Meeting Date: 12-Oct-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_370_WebXMLFile_20261007_204746791.xml)
- [Sun Pharamceutical Industries Limited has informed the Exchange about Board Meeting to be held on 12-Oct-2026 to consider Fund raising. |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_370_WebXMLFile_20261007_204746791.xml)
- [Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/SUNSEC_06102026182517_SEintimationPRforMSP.pdf)
- [Newspaper Publication about Postal Ballot/E-voting October 2026 |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SUNSEC_02102026171502_SE_intimation_for_PB_Newspaper_Advertisement.pdf)
- [Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 01, 2026, titled "New LEQSELVI® (deuruxolitinib) Two-YearData in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/SUNPHARMA123_01102026174411_SEIntimationPR_1Oct2026.pdf)
- [Notice of Postal Ballot October 2026 |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/SUNSEC_01102026184724_SEintimationfornoticeofpostalballot.pdf)
- [Sun Pharmaceutical Industries Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot |SUBJECT: Notice Of Shareholders Meetings-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_370_WebXMLFile_20261001_185747006.xml)

### FAQs

**What is Sun Pharma's plan for fundraising, and when will it be considered?**

Sun Pharma's board is scheduled to consider a Non-Convertible Debenture (NCD) issue of up to ₹15,000 crore on October 12, 2026. The debentures are proposed to be issued through private placement in one or more tranches.

**What recent corporate actions or announcements has Sun Pharma made?**

On October 6, 2026, Sun Pharma established the Sun Professorship in Dermatology at the Icahn School of Medicine at Mount Sinai through a $2.5 million endowment. Additionally, the company has informed the exchange about a board meeting on October 12, 2026, to consider fundraising, and has published notices regarding a postal ballot/e-voting process in October 2026.

**What are Sun Pharma's recent performance returns and volatility metrics?**

As of October 12, 2026, Sun Pharma's recent returns include +5.3% over the last year, +2.3% year-to-date, and -4.3% over the last month. The stock has shown annualized volatility of +20.5% and a current drawdown of -12.0%, with a maximum drawdown of -17.3%.

**What are the key technical support and resistance levels for Sun Pharma?**

The nearest technical resistance levels for Sun Pharma are at ₹1762.6 (0.15% above current price), ₹1765.64 (0.32% above current price), ₹1774.2 (0.81% above current price), and ₹1788.4 (1.61% above current price). Key support levels are identified at ₹1748.4 (0.66% below current price), ₹1736.8 (1.32% below current price), ₹1726.12 (1.93% below current price), and ₹1722.6 (2.12% below current price).

- [Indian pharma leaders seek faster trials, state-backed market for new drugs](https://www.businesstoday.in/industry/pharma/story/indian-pharma-leaders-seek-faster-trials-state-backed-market-for-new-drugs-560883-2026-10-11)
- [Sun Pharmaceutical board to consider ₹15,000 crore NCD issue on October 12](https://www.cnbctv18.com/market/stocks/sun-pharmaceutical-share-price-board-to-consider-rs-15000-crore-ncd-issue-on-october-12-20007048.htm)
- [Other business matters |Meeting Date: 12-Oct-2026](https://nsearchives.nseindia.com/corporate/SUNSEC_07102026203800_SEintimationofBMforNCD.pdf)
- [Board Meeting Intimation |Meeting Date: 12-Oct-2026](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_370_WebXMLFile_20261007_204746791.xml)
- [Sun Pharamceutical Industries Limited has informed the Exchange about Board Meeting to be held on 12-Oct-2026 to consider Fund raising. |SUBJECT: Board Meeting Intimation](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_370_WebXMLFile_20261007_204746791.xml)
- [Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/SUNSEC_06102026182517_SEintimationPRforMSP.pdf)
- [Newspaper Publication about Postal Ballot/E-voting October 2026 |SUBJECT: Copy of Newspaper Publication](https://nsearchives.nseindia.com/corporate/SUNSEC_02102026171502_SE_intimation_for_PB_Newspaper_Advertisement.pdf)
- [Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated October 01, 2026, titled "New LEQSELVI® (deuruxolitinib) Two-YearData in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026". |SUBJECT: Press Release](https://nsearchives.nseindia.com/corporate/SUNPHARMA123_01102026174411_SEIntimationPR_1Oct2026.pdf)
- [Notice of Postal Ballot October 2026 |SUBJECT: Shareholders meeting](https://nsearchives.nseindia.com/corporate/SUNSEC_01102026184724_SEintimationfornoticeofpostalballot.pdf)
- [Sun Pharmaceutical Industries Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot |SUBJECT: Notice Of Shareholders Meetings-XBRL](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_370_WebXMLFile_20261001_185747006.xml)
## Technical analytics

- As of: 2026-10-13
- Daily trend: Moderate Downtrend
- Weekly trend: Weak Downtrend
- Pivot point: ₹1,762.2
- Risk regime: Price Risk Currently Contained

### Support levels
- 1735.5587875366211
- 1664.72294921875
- 1621.768408203125

### Resistance levels
- 1825.9337890625002
- 1859.9
- 1892.8

### Return and range metrics

| Metric | Value |
| --- | --- |
| return_1 | +0.61% |
| return_10 | -3.66% |
| return_1m | -3.77% |
| return_1y | +6.13% |
| return_20 | -3.77% |
| return_3m | -7.84% |
| return_5 | -1.85% |
| return_6m | +7.17% |
| return_since_start | -6.31% |
| return_ytd | +2.88% |

### Risk and volatility metrics

| Metric | Value |
| --- | --- |
| state | contained_risk |
| label | Price risk currently contained |
| summary | Recent drawdown and price variability remain within the producer's contained-risk thresholds. |
| maximum_drawdown | -17.28% |
| annualized_volatility | +20.50% |

## Quarterly financials

- Latest complete quarter: fy27_q1

# Revenue rises 10.5% year-on-year; profit before tax grows 29% as exceptional charges narrow

Sun Pharmaceutical Industries Limited reported revenue of ₹15,299.88 crore for the quarter ended 30 June 2026, up 10.5% from the same quarter last year. Profit before tax increased 29.2% to ₹4,098.81 crore, partly driven by a reduction in exceptional charges from ₹818 crore to ₹204 crore. Excluding exceptional items, underlying profit before tax grew 7.8%, slower than revenue. Comprehensive income rose sharply due to a large other comprehensive income component.

## Revenue Growth

Revenue from operations was ₹15,299.88 crore, compared to ₹13,851.40 crore in the same quarter last year, an increase of 10.5%. Sequentially, revenue rose 4.7% from ₹14,611.79 crore in the preceding quarter (Q4 FY2025-26). Over the past five quarters, revenue peaked in Q3 FY2025-26 at ₹15,520.54 crore, declined in Q4, and recovered in the current quarter.

## Profitability and Exceptional Items

Profit before tax (PBT) increased 29.2% year-on-year to ₹4,098.81 crore from ₹3,172.77 crore. The prior-year quarter included an exceptional charge of ₹818 crore, while the current quarter had a smaller exceptional charge of ₹204.09 crore. Adjusting for these items, PBT before exceptional items was ₹4,302.90 crore versus ₹3,990.77 crore a year ago, a growth of 7.8% — below the revenue growth rate of 10.5%. This indicates that underlying profitability did not expand as much as the headline PBT figure suggests.

Finance costs rose to ₹99.67 crore from ₹74.80 crore a year ago, a 33.3% increase, and also increased sequentially from ₹85.89 crore in Q4. Other income for the quarter was ₹723.62 crore.

## Comprehensive Income and Other Comprehensive Income

Comprehensive income for the period was ₹4,410.38 crore, up 82.2% from ₹2,420.29 crore in the same quarter last year. This large increase was primarily due to a surge in other comprehensive income (OCI), which rose from ₹127.42 crore to ₹1,509.15 crore. OCI in the current quarter was nearly flat compared to the preceding quarter (₹1,503.37 crore). Net profit for the period was ₹2,901.23 crore, implying an effective tax rate of about 29.0% on the reported PBT.

## Cost Structure

Major operating costs for the quarter included cost of materials consumed (₹2,026.28 crore), employee benefit expense (₹3,227.23 crore), and depreciation, depletion, and amortisation (₹738.72 crore). Together, these three items accounted for 39.1% of revenue. Finance costs added another ₹99.67 crore.

## Earnings Per Share and Capital Structure

Basic and diluted earnings per share from continuing operations were ₹12.10, up from ₹9.50 a year ago, a 27.4% increase. The EPS figures for continuing and discontinued operations are identical, indicating no material impact from discontinued operations on per-share earnings. The equality of basic and diluted EPS also points to the absence of dilutive equity instruments.

## Key Takeaway

Sun Pharma’s June 2026 quarter delivered revenue growth of 10.5% year-on-year, but the 29% increase in profit before tax was significantly influenced by a reduction in exceptional charges. Underlying profit growth, excluding exceptional items, was slower than revenue growth. Comprehensive income was boosted by a large other comprehensive income component, which has been elevated in recent quarters. The company had no dilutive securities, and discontinued operations had no material effect on per-share earnings.

### Ratios

## Shareholding pattern

- Quarter: FY2027-Q1
- As of: 2026-06-30
- Promoter holding: +54.48%
- FII holding: +14.54%
- DII holding: +22.06%
- Mutual fund holding: +12.84%
- Retail holding: +4.38%
- Promoter pledged: +0.00%

### Major reported shareholders

- Shanghvi Finance Private Limited — +40.30% (Bodies Corporate)
- Dilip.S.Shanghvi — +9.60%
- Life Insurance Corporation Of India — +5.53%
- Icici Prudential Value Fund — +3.72%
- Sbi Nifty 50 Etf — +2.36%
- Nps Trust- A/C Hdfc Pension Fund Management Limited Scheme E - Tier I — +1.88%
- Aditya Medisales Limited — +1.67% (Bodies Corporate)
- Nippon Life India Trustee Ltd-A/C Nippon India Large Cap Fund — +1.38%
- Raksha Sudhir Valia — +1.20% (Person Acting in Concert)
- Government Pension Fund Global — +1.03%

## Official filings

- 2026-10-12 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_12102026195625_BMOutcome12October2026.pdf)
- 2026-10-12 — Management Change: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_12102026200413_BMOutcome12October2026.pdf)
- 2026-10-12 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CIM_370_WebXMLFile_20261012_203440025.xml)
- 2026-10-12 — Management Change: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNPHARMA_ROID_100278_KMP_Doc.zip)
- 2026-10-07 — Board Meeting Notice: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_07102026203800_SEintimationofBMforNCD.pdf)
- 2026-10-07 — Board Meeting Notice: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_370_WebXMLFile_20261007_204746791.xml)
- 2026-10-07 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/PRIOR_INTIMATION_370_WebXMLFile_20261007_204746791.xml)
- 2026-10-06 — Press Release: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_06102026182517_SEintimationPRforMSP.pdf)
- 2026-10-02 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_02102026171502_SE_intimation_for_PB_Newspaper_Advertisement.pdf)
- 2026-10-01 — Press Release: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNPHARMA123_01102026174411_SEIntimationPR_1Oct2026.pdf)
- 2026-10-01 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_01102026184724_SEintimationfornoticeofpostalballot.pdf)
- 2026-10-01 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/NOTICE_OF_SHAREHOLDERS_MEETINGS_370_WebXMLFile_20261001_185747006.xml)
- 2026-09-30 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_30092026174654_SEIntimationfor_Special_Window_30092026.pdf)
- 2026-09-29 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_29092026192130_ESGOVerview2025-26.pdf)
- 2026-09-28 — Press Release: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_28092026082027_SE_Intimation_of_PR_for_lerodalcibep_licensing.pdf)
- 2026-09-28 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_28092026200828_SEIntimationforVR.pdf)
- 2026-09-25 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/CLOSURE_TRADING_WINDOW_370_WebXMLFile_20260925_175430427.xml)
- 2026-09-25 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_25092026175214_SEintimationforCTW.pdf)
- 2026-09-22 — Earnings Presentation: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNPHARMA456_22092026192814_IntimationSE20260922_Investor_Presenatation_Sept2026_Signed.pdf)
- 2026-09-11 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_11092026195640_SEIntimationGxMDLSept2026.pdf)
- 2026-09-09 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_09092026145813_SEIntimationforGTCIncorporation.pdf)
- 2026-09-09 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/xbrl/REG30_Restructuring_370_WebXMLFile_20260909_150732419.xml)
- 2026-09-08 — Credit Rating Update: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_08092026203827_SEIntimationforInternationalCreditRatings.pdf)
- 2026-09-03 — Generic Announcement: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNPHARMA456_03092026160827_IntimationSE20260903_for_Analyst_and_Investor_meeting_Signed.pdf)
- 2026-08-31 — Press Release: Sun Pharmaceutical Industries Limited — [Official attachment](https://nsearchives.nseindia.com/corporate/SUNSEC_01092026014518_SEintimationPRforwhitehouse.pdf)

## News and market events

- 2026-10-11 — BUSINESSTODAY: **Indian pharma leaders seek faster trials, state-backed market for new drugs** — Indian pharmaceutical industry, innovative medicines India, clinical trials India, pharma regulatory challenges, Sun Pharma Organon acquisition, Glenmark AbbVie deal, pharma R&D investment, Indian pharma global expansion, IFQM Symposium 2026, pharma market access India — [Source](https://www.businesstoday.in/industry/pharma/story/indian-pharma-leaders-seek-faster-trials-state-backed-market-for-new-drugs-560883-2026-10-11)
- 2026-10-07 — CNBC-TV18: **Sun Pharmaceutical board to consider ₹15,000 crore NCD issue on October 12** — Sun Pharma’s board will consider an NCD issue of up to ₹15,000 crore on October 12. The debentures are proposed to be issued through private placement in one or more tranches. — [Source](https://www.cnbctv18.com/market/stocks/sun-pharmaceutical-share-price-board-to-consider-rs-15000-crore-ncd-issue-on-october-12-20007048.htm)
- 2026-10-05 — Economic Times: **Indian companies must invest in R&D, move from generics to innovation-led industry: Pharma leaders** — Indian pharmaceutical leaders emphasize the need for investment in innovation to transition from generics to innovative products. They highlight the importance of regulatory reforms and a strong ecosystem for research and development. Industry executives mention that the next decade will be critical for this transformation and urge companies to capitalize on scientific talent. Government initiatives are acknowledged as supportive in this endeavor for global competitiveness. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/indian-pharma-industry-urged-to-shift-from-generics-to-innovation-led-growth-key-insights-from-industry-leaders/articleshow/134704527.cms)
- 2026-10-05 — MONEYCONTROL: **Healthcare, pharma shares extend decline for 3rd day; Sun Pharma, Dr. Reddy's among top losers** — stock — [Source](https://www.moneycontrol.com/news/business/markets/healthcare-shares-extend-decline-for-3rd-day-sun-pharma-dr-reddy-s-fall-up-to-1-14044964.html)
- 2026-09-30 — Economic Times: **Globalisation 2.0, can it be furrowed home? - The Economic Times** — Indian corporations are making bold strides abroad, with Essar establishing a massive $15 billion steel complex in Iowa. Notable companies such as Tata Motors and Reliance are also venturing into international markets across diverse sectors. However, the declining investments from mid-level Indian firms raise concerns about potential impacts on employment and economic growth at home. The ongoing debate is whether Globalisation 2. — [Source](https://economictimes.indiatimes.com/opinion/et-editorial/globalisation-2-0-can-it-be-furrowed-home/articleshow/134600241.cms)
- 2026-09-29 — Economic Times: **Sun Pharma plans $1 billion local debt sale for loan takeout, sources say** — Sun Pharma is planning to raise about Rs 10,000 crore through rupee-denominated bonds to partly refinance a bridge loan used for its Organon acquisition, according to Reuters. The drugmaker is expected to issue two-, three- and four-year bonds as Indian companies increasingly turn to domestic debt amid high US borrowing costs and expectations of an RBI rate hike. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-plans-1-billion-local-debt-sale-for-loan-takeout-sources-say/articleshow/134562569.cms)
- 2026-09-29 — MONEYCONTROL: **Pharma stocks gain on US tariff exemption on some specialty drugs** — pharma stocks — [Source](https://www.moneycontrol.com/news/business/markets/pharma-stocks-gain-on-us-tariff-exemption-on-some-specialty-drugs-14040978.html)
- 2026-09-29 — Mint: **Crude oil shock and higher yields: Why Indian stock markets may remain volatile in near term - where should you invest?** — With Indian equities under pressure from high crude prices and rising bond yields, experts recommend a cautious investment approach. Focus on accumulating high-quality stocks while monitoring key factors. Tailored strategies emphasize technical analysis and sector strength amidst ongoing volatility. — [Source](https://www.livemint.com/market/stock-market-news/crude-oil-shock-and-higher-yields-why-indian-stock-markets-may-remain-volatile-in-near-term-where-should-you-invest-11790665625517.html)
- 2026-09-29 — Economic Times: **Why is market falling today? Sensex slumps 700 points, Nifty below 22,600. 8 key factors rattling D-Street** — On Tuesday, the Indian stock market faced a substantial downturn. This sharp decline came after a previous drop exceeding 1.5% the day before. A staggering Rs 4 lakh crore was wiped off in market capitalisation, as investors reacted to rising oil prices and climbing bond yields. — [Source](https://economictimes.indiatimes.com/markets/stocks/news/why-is-market-falling-today-sensex-slumps-700-points-nifty-below-22600-8-key-factors-rattling-d-street/articleshow/134555814.cms)
- 2026-09-29 — BUSINESSTODAY: **Pharma stocks: Sun Pharma, Dr Reddy’s, Cipla, Biocon and others in focus today; here's why** — Pharma stocks, Sun Pharma, Dr Reddy’s, Cipla, Biocon — [Source](https://www.businesstoday.in/markets/trending-stocks/story/pharma-stocks-sun-pharma-dr-reddys-cipla-biocon-others-in-focus-today-heres-why-558401-2026-09-29)
- 2026-09-28 — The Hindu: **Sun Pharma inks pact with LIB Therapeutics to sell LDL-C drug** — Sun Pharma inks exclusive licensing with LIB Therapeutics to commercialize lerodalcibep worldwide (excluding U.S. and China) for LDL-C reduction. — [Source](https://www.thehindu.com/business/Industry/sun-pharma-inks-pact-with-lib-therapeutics-to-sell-ldl-c-drug/article71520428.ece)
- 2026-09-28 — Economic Times: **Sun Pharma signs major deal with LIB Therapeutics of US, gains access to $3.7-bn global market for bad cholesterol inhibitor PCSK9** — Sun Pharma has signed an exclusive agreement with LIB Therapeutics for Lerodalcibep, a cholesterol-lowering medication. This deal covers all markets globally except for the United States and China. Lerodalcibep, a once-monthly PCSK9 inhibitor, will be marketed under the name Lyrokaul in Europe. — [Source](https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/sun-pharma-signs-major-deal-with-lib-therapeutics-of-us-gains-access-to-3-7-bn-global-market-for-bad-cholesterol-inhibitor-pcsk9/articleshow/134533716.cms)
- 2026-09-28 — BUSINESSTODAY: **Sun Pharma shares in focus after global licensing deal for cholesterol drug; check details** — Sun Pharma shares, Sun Pharmaceutical Industries Ltd, Sun Pharma stock, Sun Pharma share price, Sun Pharma lerodalcibep, lerodalcibep, Lyrokaul, PCSK9 inhibitor, LIB Therapeutics, Sun Pharma licensing deal, cholesterol drug, cardiovascular drugs, pharma stocks, innovative medicines, PCSK9 market — [Source](https://www.businesstoday.in/markets/stocks/story/sun-pharma-shares-in-focus-after-global-licensing-deal-for-cholesterol-drug-check-details-558123-2026-09-28)
- 2026-09-28 — BUSINESS: **Sun Pharma signs exclusive licensing agreement with LIB Therapeutics Inc.** — To commercialize and manufacture Lerodalcibep worldwide, excluding the United States and China — [Source](https://www.business-standard.com/markets/capital-market-news/sun-pharma-signs-exclusive-licensing-agreement-with-lib-therapeutics-inc-126092800111_1.html)
- 2026-09-28 — Economic Times: **Breaking News Live: China-US trade truce extended to January 2027; Beijing outlines coal, AI and finance cooperation - The Economic Times** — Breaking News Live Updates: China and the US have agreed to extend their trade truce to January 2027, while also expanding cooperation in coal, agriculture, AI, finance and flights. — [Source](https://economictimes.indiatimes.com/news/newsblogs/breaking-news-election-commission-live-updates-politics-bjp-congress-cec-gyanesh-kumar-resignation-cockroach-janta-party-ufbu-bank-strike-news-today-us-iran-war-trump-us-midterm-elections-china-weather-today-september-28/liveblog/134529611.cms)
- 2026-09-27 — The Hindu: **TNPCB tells NGT Sun Pharma did not implement proposed expansion in Chengalpattu** — TNPCB informs NGT Sun Pharma’s Chengalpattu unit operates within existing capacity, lacking consent to operate for expansion. — [Source](https://www.thehindu.com/news/cities/chennai/tnpcb-tells-ngt-sun-pharma-did-not-implement-proposed-expansion-in-chengalpattu/article71515736.ece)
- 2026-09-24 — Mint: **India-Mexico may sign trade pact, report reveals: Autos, pharma, engineering—who stands to gain? | Mint** — India and Mexico are set to finalize the Terms of Reference for a preferential trade agreement in early October, focusing on trade facilitation and market access. This could boost Indian exports, particularly in automobiles and pharmaceuticals, despite upcoming tariffs on imports from India. — [Source](https://www.livemint.com/economy/indiamexico-may-sign-trade-pact-report-reveals-autos-pharma-engineering-who-stands-to-gain-11790259606449.html)
- 2026-09-24 — Mint: **NSE shares trump HUL! Enters top 10 list of Indian stocks in terms of market capitalization** — NSE shares debuted at ₹1,800 on September 24, rising to an intraday high of ₹1,878. With a market capitalization of ₹4.63 lakh crore, NSE becomes the ninth-largest listed company in India, surpassing major firms like HUL and Sun Pharma. — [Source](https://www.livemint.com/market/stock-market-news/nse-shares-trump-hul-enters-top-10-list-of-indian-stocks-in-terms-of-market-capitalization-11790228790916.html)
- 2026-09-22 — MONEYCONTROL: **Trade Spotlight: How should you trade Deepak Fertilisers, Lupin, Muthoot Finance, Sapphire Foods, Samvardhana Motherson, and others on September 22?** — Trade Spotlight, Buy Ideas,Top Buy Ideas,Top Picks,Stock Picks,Top Stock Picks,Share Tips,Share Market Tips,Stock Tips,Stock Market Tips,Deepak Fertilisers and Petrochemicals Corporation,Jubilant Foodworks,HDFC Life Insurance Company,ITC,Lupin,Muthoot Finance,Sun Pharmaceutical Industries,Sapphire Foods India,Samvardhana Motherson International — [Source](https://www.moneycontrol.com/news/business/markets/trade-spotlight-how-should-you-trade-deepak-fertilisers-lupin-muthoot-finance-sapphire-foods-samvardhana-motherson-and-others-on-september-22-14034929.html)
- 2026-09-21 — Mint: **JP Morgan’s new India chief Rahul Badhwar aims for top spot in wholesale banking | Company Business News** — Badhwar, who joined as senior country officer in July, plans to double down on dealmaking and corporate lending to outpace rivals, even as rich valuations and rising US yields spur foreign outflows. — [Source](https://www.livemint.com/companies/news/jp-morgan-s-new-india-chief-rahul-badhwar-aims-for-top-spot-in-wholesale-banking-11789993937894.html)
- 2026-09-21 — The Hindu: **Broker’s Call: Sun Pharma (Buy)** — Geojit Investments — [Source](https://www.thehindubusinessline.com/markets/brokers-call-sun-pharma-buy/article71491254.ece)
- 2026-09-21 — MONEYCONTROL: **Pharma stocks rise up to 6% amid defensive buying, strong product pipeline; Mankind Pharma, Wockhardt lead gains** — Pharma stocks, Sun Pharma — [Source](https://www.moneycontrol.com/news/business/markets/pharma-stocks-rise-up-to-6-amid-defensive-buying-strong-product-pipeline-mankind-pharma-wockhardt-lead-gains-14034517.html)
- 2026-09-21 — MONEYCONTROL: **Buy Sun Pharmaceutical Industries; target of Rs 2070: Geojit Financial Services** — Geojit Financial Services, Sun Pharmaceutical Industries, buy, Recommendations — [Source](https://www.moneycontrol.com/news/business/stocks/buy-sun-pharmaceutical-industries-target-of-rs-2070-geojit-financial-services-14034494.html)
- 2026-09-16 — Mint: **Domestic pharma market sustains growth momentum, but margins remain key** — Domestic pharma growth remained strong in August, led by price hikes and new launches, but weak volumes and US tariff uncertainty mean a sustained margin recovery will be crucial for sector performance. — [Source](https://www.livemint.com/market/mark-to-market/indian-pharma-market-ipm-pharma-stocks-domestic-pharma-dr-reddy-s-laboratories-sun-pharma-ajanta-pharma-glenmark-11789538290089.html)
- 2026-09-15 — Mint: **Delhi HC orders tax dept to refund ₹783 cr to Teva Israel over Ranbaxy payment | Company Business News** — This brings relief to Teva in a nearly nine-year-old court battle over the payments linked to erstwhile Ranbaxy, now part of Sun Pharmaceutical Industries — [Source](https://www.livemint.com/companies/delhi-hc-tax-refund-to-teva-israel-ranbaxy-sun-pharma-income-tax-india-11789467986662.html)

## Business profile

**Strategic vision:** Develops, manufactures, and commercializes pharmaceutical products globally.

### Business segments
- **Branded and Generic Formulations:** Manufactures finished oral solid dosages, injectables, liquids, and ointments marketed across cardiovascular, neuropsychiatry, gastroenterology, and anti-infective therapeutic segments.
- **Specialty Medicines:** Develops and commercializes proprietary, clinically differentiated medicines primarily in dermatology, ophthalmology, and oncology.
- **Active Pharmaceutical Ingredients (APIs):** Produces bulk chemical substances, including peptides, steroids, and cytotoxic active ingredients for captive use and export to global pharmaceutical manufacturers.

### Competitive strengths
- Vertically integrated manufacturing operations
- Diverse portfolio of generic, branded generic, and specialty pharmaceutical products
- In-house API production capabilities
- Global research and development centers

## Related stocks

- [Apollo Hospitals Enterprise Limited (Healthcare)](https://faxioms.com/stocks/apollohosp) — +1.29%
- [Cipla Limited (Healthcare)](https://faxioms.com/stocks/cipla) — +1.40%
- [Dr. Reddy's Laboratories Limited (Healthcare)](https://faxioms.com/stocks/drreddy) — +0.86%
- [Max Healthcare Institute Limited (Healthcare)](https://faxioms.com/stocks/maxhealth) — -0.57%
- [Divi's Laboratories Limited (Healthcare)](https://faxioms.com/stocks/divislab) — -1.50%

## Freshness and sources

- Data as of: 2026-10-13
- Source: Faxioms public stock analysis API

Canonical: https://faxioms.com/stocks/sunpharma
Markdown representation: https://faxioms.com/stocks/sunpharma?render=md